Revolution Medicines, Inc.
Revolution Medicines (Nasdaq: RVMD) is a clinical-stage precision oncology company developing targeted therapies for cancers driven by RAS mutations. Its pipeline centers on small-molecule RAS(ON) inhibitors, which target the active form of RAS, including daraxonrasib, a multi-selective inhibitor, and the… From the company’s description.
In fiscal 2025, Revolution Medicines, Inc. reported revenue of $0.00M and a net loss of $1.13B. Operations used $897.74M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Revolution Medicines, Inc. does
In the company’s own words
Revolution Medicines (Nasdaq: RVMD) is a clinical-stage precision oncology company developing targeted therapies for cancers driven by RAS mutations. Its pipeline centers on small-molecule RAS(ON) inhibitors, which target the active form of RAS, including daraxonrasib, a multi-selective inhibitor, and the mutation-selective candidates zoldonrasib, elironrasib and RMC-5127. The company is evaluating these candidates as monotherapies and in combinations with other RAS inhibitors, standard cancer treatments and investigational therapies, with clinical programs in pancreatic, lung and colorectal cancers. Its proprietary tri-complex technology platform supports drug discovery and development; the company also collaborates with pharmaceutical and research partners on combination trials and discovery work. Revolution Medicines has no products approved for commercial sale and relies on contract manufacturers for its clinical and potential commercial supply. In fiscal 2025, it reported no product-sales revenue. The company’s main website is https://www.revmed.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1628171
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Revolution Medicines, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Revolution Medicines, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Revolution Medicines, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Revolution Medicines, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Revolution Medicines, Inc.’s debt, $137.63M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.50%, maturing 2033 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Revolution Medicines, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Revolution Medicines, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Revolution Medicines, Inc.'s last four quarterly filings that the numbers alone won't show?”